What is Bionomics Limited (BNOEF)?

Bionomics Limited (BNOEF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BNOEF?

The current price of BNOEF is $0.01. Prices are updated in real time on Stocks360.

What is BNOEF's price-to-earnings (PE) ratio?

BNOEF's trailing twelve-month PE ratio is -0.85, based on current price and earnings per share data available on Stocks360.

What is BNOEF's market capitalization?

BNOEF's market capitalization is $8,812,440.00, placing it in the small-cap tier.

Bionomics Limited (BNOEF)

Stock analysis · OTC · Healthcare · Biotechnology

$0.01

Market Cap

$8.81M

PE (TTM)

-0.85

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.84

Day Range

$0.00 – $0.01

52-wk Range

$0.00 – $0.06

Avg Volume

N/A

Volume

72.74K

Bionomics Limited (BNOEF) is a publicly traded company in the Healthcare sector. Latest price: $0.01. Market cap $8.81M. Trailing PE -0.85. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 28, 2022

EPS $-0.47 vs est. $0.85

Missed by $1.32

Proprietary Signals

Signal snapshot temporarily unavailable.

About Bionomics Limited

Bionomics Limited, an Australian clinical-stage biopharmaceutical company founded in 1996 and based in Eastwood, focuses on identifying and developing innovative drug candidates to address central nervous system conditions and various cancers. A significant experimental medicine in their pipeline is BNC210, a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor. This compound is currently undergoing a Phase 2 clinical trial for social anxiety disorder and a Phase 2b study for post-traumatic stress disorder (PTSD). The company's portfolio also includes BNC101, a monoclonal antibody designed to combat cancer stem cells, which has successfully completed its Phase 1 clinical evaluation. Additionally, Bionomics is advancing BNC105, currently in a Phase 2 clinical trial for refractory colorectal cancer and a Phase 1 trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.85×
P/S (TTM)	0.00×
P/B	0.00×
P/FCF (TTM)	-0.85×
EV / EBITDA	-0.02×
EV / Sales	0.00×
Earnings Yield	-22254650.88%
Free Cash Flow Yield	-117.16%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$195.04K
Net Income (TTM)	-$2.79T
Free Cash Flow (TTM)	-$14.68M
Net Debt	-$12.34M
Working Capital	$9.36M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-78305.87%
Return on Invested Capital	-7772.82%